BIRMINGHAM, UK – April 6, 2022 – Biomedical startup Adapttech today announced that it has raised £2.25M from investors including Mercia Asset Management, ACF Investors, Wren Capital and Wealth Club. The company also announced the launch of the new INSIGHT Range, a family of products that make it faster and easier to fit lower-limb prostheses and improve patient outcomes.  

The new funding will be used by Adapttech to further develop smart, wearable technologies to help people with physical limitations improve their quality of life. The company is the first to combine 3D scanning with dynamic pressure data, providing time and cost efficiency benefits to orthotics and prosthetics (O&P) clinics and their patients.  

The company’s flagship product, the INSIGHT system, has today been upgraded into a full product range, with several new options for O&P professionals, including: 

• INSIGHT Sense: an affordable, portable, and standalone real-time analysis pressure measurement system; targeted at smaller O&P clinics to reduce hardware costs and help them provide house calls to remote patients. 
• INSIGHT Digitizer: a standalone digitizer for prosthetic sockets that creates high-resolution 3D models; targeted at central fabrication and large O&P clinic groups. 
• INSIGHT Pro: combines both the INSIGHT Digitizer and INSIGHT Sense; targeted at larger O&P clinic groups, central fabrication, and research facilities and universities. 

Frederico Carpinteiro, CEO, Adapttech, said: “With the new INSIGHT Range, we’re responding to requests for a scanner-less system, reduced hardware costs, and improved data collection. This new funding comes at a time when we are developing exciting new technologies to benefit our O&P clinic customers and their patients. We look forward to continuing our trajectory in growing our revenues, product portfolio, and international business operations.” 

Stephen Windsor, Investment Director at Mercia, said: “Adapttech brought its first product to market during 2021, successfully securing a number of sales. We are delighted to be supporting the team with a follow-on investment to continue to scale the business and build out the product portfolio.” 

Paul Fauset, Partner at ACF Investors commented: “The unique IP at the heart of Adapttech’s products means there is a great opportunity for the company to become a leader in the orthotics and prosthetics industry, with smart technologies that are improving the quality of life for users. This latest round of funding builds on the team’s success and we look forward to seeing the business grow as it accelerates product development.” 

Adapttech recently signed licensing deals with Modus Health for its StepWatch step-count software, the University of Washington for the Prosthetic Limb Users Survey of Mobility (PLUS-M) self-reporting tool, and Advanced Rehabilitation Therapy for the Amputee Mobility Predictors (AMPPro / AMPnoPro). These industry measurement tools will be incorporated into future product designs and patient outcome models. 
 

– ENDS – 

 

ABOUT ADAPTTECH 

Adapttech is a biomedical company focused on developing technologies that empower healthcare providers to help people with physical limitations to improve their quality of life. The company is supported by investors including the MEIF Proof of Concept & Early Stage Fund, Midlands Engine Investment Fund, Bionova Capital, ACF Investors, Wealth Club and Wren Capital. www.adapttech.eu    

 

PRESS CONTACT 

Danny Sullivan 

PERGALI 

T: +44 772 497 4255 

E: [email protected]